Paper · 24323902
Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.
Wick DA and 10 others. Clin Cancer Res, 2014. Cited by 131 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Papers, record 24323902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24323902
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunologic Surveillance | Major topic |
| Mutation | Major topic |
| Ovarian Neoplasms | Major topic |
| T-Lymphocytes | Major topic |
| CD8-Positive T-Lymphocytes | |
| Disease Progression | |
| Epitopes, T-Lymphocyte | |
| Female | |
| HLA Antigens | |
| Humans | |
| Hydroxysteroid Dehydrogenases | |
| Immunohistochemistry | |
| Lymphocytes, Tumor-Infiltrating | |
| Neoplasm Grading | |
| Recurrence |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by91
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 131 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,936,532 | Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Biomarkers of Ovarian Cancer in Asian Populations: A Systematic Review and Meta-analysis. | Oman Med J | 2026 | https://conductscience.org/library/papers/42936532 | PubMed |
| 41,972,540 | Long Non-Coding RNA-Derived Peptides as a Novel Source of Tumor Neoantigens: Expanding the Immunopeptidome Beyond Canonical Coding Regions. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/41972540 | PubMed |
| 39,364,290 | High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils. | Oncoimmunology | 2024 | https://conductscience.org/library/papers/39364290 | PubMed |
| 39,160,299 | A synthetic cytotoxic T cell platform for rapidly prototyping TCR function. | NPJ Precis Oncol | 2024 | https://conductscience.org/library/papers/39160299 | PubMed |
| 38,891,037 | Plasma Gelsolin Inhibits Natural Killer Cell Function and Confers Chemoresistance in Epithelial Ovarian Cancer. | Cells | 2024 | https://conductscience.org/library/papers/38891037 | PubMed |
| 38,713,894 | Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma. | Blood Adv | 2024 | https://conductscience.org/library/papers/38713894 | PubMed |
| 38,235,131 | NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens. | Front Immunol | 2023 | https://conductscience.org/library/papers/38235131 | PubMed |
| 38,067,396 | Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38067396 | PubMed |
| 37,894,429 | The Prognosis Predictive Score around Neo Adjuvant Chemotherapy (PPSN) Improves Diagnostic Efficacy in Predicting the Prognosis of Epithelial Ovarian Cancer Patients. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37894429 | PubMed |
| 37,666,898 | Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine. | Cancer Gene Ther | 2023 | https://conductscience.org/library/papers/37666898 | PubMed |
1 to 10 of 91
See all 91 cited byGenes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| HSDL1 | 83,693 | PubTator's text mining | https://conductscience.org/library/genes/83693 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24323902
GET https://conductscience.org/api/papers/v1/24323902/cited_by?page=2